Safety and Efficacy of Treating Refractory Cancers With the Litx™ System: Phase II Safety and Efficacy Study in Patients With Liver Metastases From Colorectal Cancer That Have Failed Chemotherapy
Patients that provide Informed Consent and satisfy the Eligibility Criteria will undergo CT
or ultrasound guided percutaneous placement of a single, two, three, or four light infusion
devices depending on their tumor characteristics. No more than 4 light sources will be used
at a single treatment. The light infusion devices may be used in a single lesion or in
multiple lesions.
Following radiographic confirmation of light infusion device placement, patients will
receive an intravenous dose of LS11 at 40 mg/m². One hour following completion of LS11
administration, delivery of 200 J/cm light energy will begin. The light infusion device
will then be manually removed and the patients will be observed for acute complication of
light infusion device removal. Precautions for protection from external light exposure
should be instituted beginning with the LS11 administration and be maintained as defined
throughout the study period. On day 30+5 the patient will undergo clinical assessment and
the tumor mass will be imaged using contrast enhanced spiral CT for determination of volume
and radius of the tumor size, as well as tumor necrosis. The patient may then receive 5-FU
and/or leucovorin + either irinotecan or oxaliplatin standard chemotherapy at day 30 visit.
All patients, with or without chemotherapy at day 30, will undergo final clinical assessment
and final tumor imaging evaluation using contrast CT at day 60+5 of Litx treatment.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
LSC-OL002
NCT00068068
October 2003
Name | Location |
---|---|
Virginia Mason Medical Center | Seattle, Washington 98111 |
Allegheny General Hospital | Pittsburgh, Pennsylvania 15212-4772 |
HealthOne Alliance/Presbyterian St. Lukes Medical Center | Denver, Colorado 80218 |
Eastern Carolina University, School of Medicine | Greenville, North Carolina 27858 |
University of Pennsylvania / Department of Radiation Oncology | Philadelphia, Pennsylvania 19104 |